Donanemab-azbt Application Scope

Kisunla (donanemab-azbt) is indicated for the treatment of Alzheimer’s disease in patients with mild cognitive impairment or mild dementia stage of the disease.

Characteristics

Ingredients:
- Active: Donanemab-azbt
- Excipients: Anhydrous citric acid, polysorbate 80, sodium citrate, sucrose, Water for Injection, USP
Properties:
Sterile, preservative-free, clear to opalescent, colorless to slightly yellow to slightly brown solution
Packaging Specification:
Single-dose vial, one vial per carton
Storage:
Store refrigerated at 2°C to 8°C (36°F to 46°F). Keep the vial in the outer carton to protect from light. Do not freeze or shake.
Expiry Date:
Refer to the expiration date printed on the vial label and carton.
Executive Standard:
FDA-approved labeling
Approval Number:
Biologics License Application (BLA) 761248
Date of Revision:
July 2, 2024
Manufacturer:
Eli Lilly and Company

Guidelines for the Use of Donanemab-azbt

Dosage and Administration:
Administer Kisunla as an intravenous infusion every four weeks. The recommended dosage is detailed in the prescribing information.
Adverse Reactions:
Common adverse reactions include:
- Amyloid-related imaging abnormalities (ARIA), such as brain swelling and bleeding
- Headache
- Infusion-related reactions (e.g., flu-like symptoms, nausea, vomiting)
- Hypersensitivity reactions, including anaphylaxis and angioedema
Contraindications:
Kisunla is contraindicated in patients with known serious hypersensitivity to donanemab-azbt or any of its excipients.
Precautions:
- Monitor patients for ARIA via MRI scans before and during treatment.
- Observe patients during and after infusion for signs of hypersensitivity reactions.
- Ensure appropriate patient selection based on clinical and imaging criteria.

Donanemab-azbt Interactions

Drug Interactions:
No specific drug interaction studies have been conducted with donanemab-azbt. Caution is advised when co-administering with other medications that may increase the risk of bleeding or immune reactions.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.